Compare Ascendis Pharma A/S (ASND) vs Fidelity National Information Servcs Inc (FIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Fidelity National Information Servcs Inc — how do they compare? Ascendis Pharma A/S trades at $264.02 (market cap $17.74B), while Fidelity National Information Servcs Inc trades at $42.24 (market cap $21.70B). The key difference: Fidelity National Information Servcs Inc is the larger of the two by market cap, and Fidelity National Information Servcs Inc pays a 4% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | FIS | |
|---|---|---|
Market Cap | $17.74B | $21.70B |
Sector | Health | Technology |
52-Week High | $277.18 | $81.94 |
52-Week Low | $163.32 | $37.72 |
Enterprise Value | $18.11B | $42.09B |
Dividend Yield | — | 4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
FIS trades at $41.98, up 0.89% today, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 2026, and the company shows improving profitability with a 23.35% net income margin. Positive news includes cloud banking deals with Frankfurt International Bank and First Commerce Bank, reinforcing growth in digital banking services. The stock trades below the consensus price target of $52.57, indicating potential upside.
The outlook for FIS is positive due to strategic cloud expansions and earnings momentum, but risks include high debt levels and macroeconomic pressures on lending. Wall Street consensus is bullish with 58% buy ratings, though investors should monitor debt management and competitive threats in the fintech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →
